Literature DB >> 28135124

Comparisons Between Cancer-Related and Noncancer-Related Lymphedema: An Overview of New Patients Referred to a Specialized Hospital-Based Center in Canada.

Shirin M Shallwani1,2,3, Pamela Hodgson1, Anna Towers1,4,5.   

Abstract

BACKGROUND: Lymphedema is an irreversible inflammatory condition caused by accumulated lymph fluid and is associated with chronic swelling and increased risk of cellulitis. Our objectives were to: (1) describe the patient population referred to a Canadian lymphedema center and (2) compare lymphedema characteristics between patients with cancer and patients with noncancer diagnoses. METHODS AND
RESULTS: A retrospective cohort study was conducted of new patients referred for suspected lymphedema to a hospital-based center over a 2-year period. The mean age of the patients (n = 429) was 61.4 years; 85% were female and 81% had a history of cancer. Lymphedema characteristics were primary (7%) versus secondary (92%); upper body (51%) versus lower body (45%); unilateral (74%) versus bilateral (25%); and history of cellulitis (22%). Patients with noncancer diagnoses (n = 82) were more likely than patients with cancer diagnoses (n = 347) to have a history of cellulitis (44% vs. 17%), to have bilateral (61% vs. 16%) and lower limb (89% vs. 37%) lymphedema, and to experience a long delay between symptom onset and referral (14.0 vs. 3.5 years) (p < 0.001).
CONCLUSION: Most patients referred to our lymphedema center were female with a history of cancer. However, patients with noncancer diagnoses were more likely to have bilateral lower body lymphedema with an important history of cellulitis; this subgroup is at great risk of missed and delayed diagnoses in the medical setting and of experiencing long-term issues with mobility, recurrent hospitalizations, and poor quality of life.

Entities:  

Keywords:  Lymphedema; cancer; cellulitis; noncancer

Mesh:

Year:  2017        PMID: 28135124     DOI: 10.1089/lrb.2016.0023

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  7 in total

1.  A 61-year-old woman with chronic leg lymphedema managed with complete decongestive therapy.

Authors:  Larysa Bondalevich; Stefan de Laplante
Journal:  CMAJ       Date:  2020-06-29       Impact factor: 8.262

2.  Development and Validation of the Lymphedema Symptom Intensity and Distress Survey-Lower Limb.

Authors:  Sheila H Ridner; Jennifer K Doersam; Deonni P Stolldorf; Mary S Dietrich
Journal:  Lymphat Res Biol       Date:  2018-10-24       Impact factor: 2.589

3.  Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema.

Authors:  Shirin M Shallwani; Anna Towers; Anne Newman; Shannon Salvador; Angela Yung; Lucy Gilbert; Walter H Gotlieb; Xing Zeng; Doneal Thomas
Journal:  Curr Oncol       Date:  2021-01-13       Impact factor: 3.677

4.  Lymphedema Impact and Prevalence International Study: The Canadian Data.

Authors:  David H Keast; Christine Moffatt; Ashrafunissa Janmohammad
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

5.  Primary lymphedema French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

Authors:  Stéphane Vignes; Juliette Albuisson; Laurence Champion; Joël Constans; Valérie Tauveron; Julie Malloizel; Isabelle Quéré; Laura Simon; Maria Arrault; Patrick Trévidic; Philippe Azria; Annabel Maruani
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

6.  Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.

Authors:  Makoto Nishio; Terufumi Kato; Ryo Toyozawa; Toyoaki Hida
Journal:  Target Oncol       Date:  2022-09-10       Impact factor: 4.864

Review 7.  Lipedema: A Call to Action!

Authors:  Giacomo Buso; Michele Depairon; Didier Tomson; Wassim Raffoul; Roberto Vettor; Lucia Mazzolai
Journal:  Obesity (Silver Spring)       Date:  2019-10       Impact factor: 5.002

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.